ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy.Advanced pharmaceutical bulletin · 2025Review
- Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells.Acta pharmacologica Sinica · 2024Article
- Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Molecular therapy oncolytics · 2022Review
- Measles Virus as an Oncolytic Immunotherapy.Cancers · 2021Review
- Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses.Human gene therapy · 2020Article
- Review
- For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Current cancer drug targets · 2018Review
- Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus.Molecular therapy oncolytics · 2017Article
- Potential and clinical translation of oncolytic measles viruses.Expert opinion on biological therapy · 2017Review
- Review
- Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.Human vaccines & immunotherapeutics · 2016Review
- Targeting tumor vasculature through oncolytic virotherapy: recent advances.Oncolytic virotherapy · 2015Review
- Review
- Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.Journal of virology · 2013Article
- Oncolytic measles virus strains as novel anticancer agents.Expert opinion on biological therapy · 2013Review
- Cell carriers for oncolytic viruses: current challenges and future directions.Oncolytic virotherapy · 2013Review
- Oncolytic virotherapy: the questions and the promise.Oncolytic virotherapy · 2013Review
- Oncolytic virotherapy.Nature biotechnology · 2012Review
- Attenuated oncolytic measles virus strains as cancer therapeutics.Current pharmaceutical biotechnology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Systemically administered vectors must cross the endothelial lining of tumor blood vessels to access cancer cells. Vectors that interact with markers on the lumenal surface of these endothelial cells might have enhanced tumor localization. Here, we generated oncolytic measles viruses (MVs) displaying alpha(v)beta(3) integrin-binding peptides, cyclic arginine-glycine-aspartate (RGD) or echistatin, on the measles hemagglutinin protein. Both viruses had expanded tropisms, and efficiently entered target cells via binding to integrins, but also retained their native tropisms for CD46 and signaling lymphocyte activation molecule (SLAM). When fluorescently labeled and injected intravascularly into chick chorioallantoic membranes (CAMs), in contrast to unmodified viruses, the integrin-binding viral particles bound to the lumenal surface of the developing chick neovessels and infected the CAM vascular endothelial cells. In a mouse model of VEGF-induced angiogenesis in the ear pinna, the integrin-binding viruses, but not the parental virus, infected cells at sites of new blood vessel formation. When given intravenously to mice bearing tumor xenografts, the integrin-binding virus infected endothelial cells of tumor neovessels in addition to tumor parenchyma. To our knowledge, this is the first report demonstrating that oncolytic MVs can be engineered to target the lumenal endothelial surface of newly formed blood vessels when administered intravenously in living animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.